nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
Titel:
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
Auteur:
Yardley, D.A. Coleman, R. Conte, P. Cortes, J. Brufsky, A. Shtivelband, M. Young, R. Bengala, C. Ali, H. Eakel, J. Schneeweiss, A. de la Cruz-Merino, L. Wilks, S. O’Shaughnessy, J. Glück, S. Li, H. Miller, J. Barton, D. Harbeck, N.